Should Employers Cover Weight-Loss Medications? A Strategic Approach

The Scale of the Problem Employers Are Paying For Already

Obesity-related medical spending among U.S. Adults reached an estimated $173 billion annually, according to CDC data, and a substantial share of that cost lands on self-insured employer health plans. Before debating whether to add GLP-1 coverage, plan sponsors need to see the baseline they are already absorbing.

Obesity Costs That Show Up in Existing Claims

Employees with obesity generate, on average, $1,861 more in annual medical costs than employees at a healthy weight, based on analysis published in the Journal of Occupational and Environmental Medicine [1]. Those excess costs concentrate in cardiovascular events, type 2 diabetes management, orthopedic procedures, and sleep-disorder treatment, all conditions that GLP-1 receptor agonists directly modify.

The CDC estimates that 41.9% of U.S. Adults have obesity, a figure that applies roughly to most large employer populations [2]. If a plan covers 10,000 lives and 40% have obesity-related risk, that is 4,000 potential beneficiaries, a number that makes the math of GLP-1 coverage both compelling and sobering at the same time.

What "Do Nothing" Actually Costs

Employers who exclude GLP-1s still pay for the downstream conditions those drugs prevent. A 2023 analysis in JAMA Health Forum modeled a hypothetical 10,000-employee plan and found that covering semaglutide for eligible members produced lower five-year total medical expenditure than exclusion, driven largely by reduced hospitalizations for acute coronary syndrome and heart failure [3]. The break-even point in that model arrived at approximately 3.4 years for members with established cardiovascular disease.

What the Clinical Evidence Actually Shows

Coverage decisions should rest on trial evidence, not manufacturer projections. Three landmark trials define what GLP-1 drugs can do when used consistently.

STEP-1: The Weight Loss Benchmark for Semaglutide

In STEP-1 (N=1,961), adults with a BMI of 30 or higher (or BMI ≥27 with at least one comorbidity) received semaglutide 2.4 mg subcutaneously once weekly or placebo alongside a lifestyle intervention for 68 weeks. The semaglutide group achieved a mean weight loss of 14.9% of body weight versus 2.4% in the placebo group (P<0.001) [4]. About 86% of the semaglutide group achieved at least 5% weight loss, compared with 32% on placebo.

Those numbers translate clinically. A 100 kg employee losing 15 kg typically sees meaningful reductions in hemoglobin A1c, systolic blood pressure, and low-density lipoprotein cholesterol, each of which drives future claims costs.

SURMOUNT-1: Tirzepatide Sets a New Efficacy Ceiling

SURMOUNT-1 (N=2,539) tested tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, at doses of 5 mg, 10 mg, and 15 mg weekly over 72 weeks. The 15 mg dose produced a mean weight reduction of 20.9% versus 3.1% for placebo (P<0.001) [5]. Nearly 57% of participants on 15 mg lost at least 20% of body weight.

For plan sponsors, tirzepatide's superior efficacy at comparable list prices to semaglutide shifts the cost-per-kilogram-lost calculation in favor of tirzepatide for high-BMI members when both drugs are covered.

SELECT: The Cardiovascular Outcome That Changes Everything

The SELECT trial enrolled 17,604 adults with pre-existing cardiovascular disease and overweight or obesity (no diabetes required). After a mean follow-up of 34.2 months, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001) [6]. This was the first large randomized trial to demonstrate cardiovascular event reduction from a weight-loss drug in a non-diabetic population.

The SELECT result is the single most important piece of evidence for employer plan designers, because it links GLP-1 coverage directly to avoided hospitalizations, the largest single driver of self-insured plan costs.

FDA Approval Criteria: The Eligibility Floor for Any Coverage Policy

The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher in the presence of at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [7]. Tirzepatide (Zepbound) received approval under identical BMI criteria in November 2023 [8].

Why Employers Should Respect, Not Undercut, These Thresholds

Some plan administrators consider narrowing coverage to BMI ≥35 to control volume. That approach conflicts with guideline-recommended care. The American Heart Association and American College of Cardiology 2023 obesity guideline explicitly states that pharmacotherapy is appropriate for adults with a BMI of 27 or higher plus at least one adiposity-related comorbidity, not just those with severe obesity [9].

Restricting coverage below FDA-approved thresholds exposes the plan to adverse-selection problems: sicker, higher-BMI employees who qualify under a restrictive plan are precisely the members with the highest downstream costs per year. Covering a broader, moderately obese population dilutes per-member risk and improves the actuarial profile.

Contraindications the Plan Should Screen For

Any employer policy must exclude members with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, as both semaglutide and tirzepatide carry a boxed warning for these conditions [7]. Pregnancy, severe renal impairment, and active pancreatitis also require clinical review before initiation.

The Real Cost Structure: What Plan Sponsors Are Actually Buying

List price for Wegovy runs approximately $1,349 per month (roughly $16,188 per year) as of mid-2025. Zepbound carries a similar list price. After pharmacy benefit manager (PBM) rebates, typically 20%, 35% for preferred placement, net costs can fall to roughly $9,000, $13,000 per member per year for plans with negotiated contracts.

Breaking Down the Per-Member ROI Calculation

For an employee with obesity and established cardiovascular disease, the annual excess medical cost attributable to obesity-related conditions is estimated at $3,500, $6,500 per year based on published actuarial literature [1]. A GLP-1 drug at net cost of $10,000 per year does not pay for itself in year one for that member.

The ROI calculation depends on: (1) how long the member stays on therapy and sustains weight loss, (2) how many cardiovascular events are avoided over three to five years, and (3) what comorbidities the member carries at baseline. The SELECT trial's 20% cardiovascular event reduction [6] is the most powerful actuarial input, because a single avoided hospitalization for acute MI costs a self-insured plan $30,000, $90,000 depending on complexity.

Adherence Is the Variable That Destroys ROI When Ignored

Real-world claims data from U.S. Commercial plans show that approximately 50% of patients prescribed GLP-1 drugs discontinue within 12 months [10]. Discontinuation means the employer paid for several months of drug cost and received none of the long-term cardiovascular or metabolic benefit. Weight regain after stopping semaglutide averages approximately two-thirds of lost weight within one year, as demonstrated in the STEP-4 withdrawal trial (N=803) [11].

Employers who simply add GLP-1s to the formulary without a structured adherence program are likely to see poor ROI. Those who pair coverage with quarterly check-ins, registered dietitian access, and behavioral health support report meaningfully higher 12-month persistence in internal program reviews.

Designing an Employer Coverage Policy That Produces Results

A coverage policy that works clinically and financially requires at least five structural elements. These are not manufacturer recommendations; they reflect the convergence of clinical guidelines, real-world adherence data, and actuarial modeling.

Element 1: Clinical Eligibility Gates

Require documentation of BMI at or above FDA thresholds (BMI ≥30, or BMI ≥27 with comorbidity) confirmed by a covered provider visit within the prior six months. The American Gastroenterological Association recommends that clinicians document obesity-related comorbidities at baseline to guide treatment selection and monitoring [12].

Prior authorization should include: (a) confirmation of BMI threshold, (b) documentation of at least one failed three-month lifestyle intervention, and (c) absence of labeled contraindications. This three-step gate is consistent with the Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy [13].

Element 2: Outcomes-Based Continuation Criteria

Require a documented weight loss of at least 4%, 5% of baseline body weight after 16 weeks of treatment to continue coverage. This threshold mirrors clinical practice: the FDA label for Wegovy states that if 5% weight loss is not achieved by week 16 on the maintenance dose, the drug should be discontinued because continued benefit is unlikely [7].

Tying continuation to outcomes protects the plan from paying indefinitely for non-responders while keeping coverage open for the majority of patients who do respond.

Element 3: Mandatory Lifestyle Support Enrollment

Coverage should require concurrent enrollment in a structured lifestyle program. The Diabetes Prevention Program Outcomes Study (N=1,079, 15-year follow-up) showed that lifestyle intervention alone produced sustained 5%, 7% weight loss and reduced diabetes incidence by 27% at 15 years [14]. GLP-1 drugs on top of lifestyle produce additive benefit, but lifestyle support also improves adherence and sustains weight loss during any drug interruption.

Element 4: Defined Formulary Preference

Plans should designate one GLP-1 as the preferred agent (typically whichever carries the strongest PBM rebate or lowest net cost after negotiation) and require step-through from that agent before authorizing an alternative. Allowing unrestricted choice between semaglutide and tirzepatide without a step-therapy requirement adds unnecessary cost without demonstrated outcome differences at the population level.

Element 5: Reassessment at 12 Months

At 12 months, the treating clinician should document: percentage weight loss achieved, change in relevant comorbidities (A1c, blood pressure, lipid panel), and any adverse events. Members who meet continuation thresholds and have comorbidity improvement should have coverage renewed. Members who have not lost at least 5% of body weight at 12 months, despite 16-week continuation criteria being met, warrant a clinical review to determine whether dose adjustment, drug switch, or program modification is appropriate.

Legal, Regulatory, and Equity Considerations

Employer health plans governed by ERISA must apply coverage criteria consistently across similarly situated participants. Designing a GLP-1 benefit that de facto excludes lower-wage workers (for example, by requiring frequent in-person visits that hourly employees cannot attend) may create parity and equity issues.

Mental Health Parity Implications

Obesity is classified as a disease by the American Medical Association [15]. Plans that cover other chronic diseases, such as rheumatoid arthritis biologics costing $20,000 to $40,000 per year, face internal consistency questions if they exclude GLP-1s. Legal counsel familiar with ERISA and the Mental Health Parity and Addiction Equity Act should review any exclusion policy before implementation.

Coverage Disparities Across Income Levels

A 2024 study in Health Affairs found that GLP-1 uptake was significantly lower among Medicaid enrollees and lower-income commercially insured members compared with higher-income groups, despite similar obesity prevalence, largely driven by cost-sharing differences [16]. Employers who add $150 or more monthly copays for GLP-1s effectively exclude lower-wage employees from the benefit.

The American Diabetes Association's Standards of Medical Care explicitly notes that cost and access barriers should not determine treatment selection when a drug is medically indicated [17]. Plan designers who want equitable outcomes should tier GLP-1 copays at levels comparable to other specialty medications in the formulary, not at out-of-pocket maximums.

What Employers Who Have Covered GLP-1s Report

Several large U.S. Employers, including JPMorgan Chase and Novo Nordisk (the manufacturer, which covers its own employees under generous terms), have publicly discussed GLP-1 coverage. JPMorgan's benefits team reported in 2024 that GLP-1 drug spend was the single largest driver of specialty pharmacy cost growth year-over-year, reflecting rapid uptake.

Those who implemented structured programs with prior authorization, lifestyle program requirements, and outcomes-based continuation reported meaningfully lower per-member costs and higher persistence rates compared with open formulary approaches, consistent with what actuarial firms such as Milliman have modeled in published analyses.

A plan that covers GLP-1s without a structured program should expect penetration of 3%, 6% of the eligible population, high discontinuation within 12 months, and limited actuarial savings in years one and two. A plan with all five structural elements described above may see net positive impact beginning in year three for members with cardiovascular comorbidities.

How to Phase In Coverage Without Catastrophic Year-One Cost Shock

Starting with a defined high-risk cohort, members with obesity plus documented cardiovascular disease, type 2 diabetes, or obstructive sleep apnea, captures those with the highest expected downstream claim reduction per dollar spent on the drug.

Year one: cover members with BMI ≥30 plus at least two comorbidities. This limits initial volume while generating outcomes data from the highest-ROI subgroup.

Year two: expand to BMI ≥27 plus one comorbidity if year-one program data support projected break-even at or before 36 months.

Year three: evaluate full FDA-label eligibility coverage based on accumulated cost, outcomes, and persistence data from your own enrolled population.

This phased approach is consistent with how large plan sponsors typically introduce high-cost specialty drugs and gives the benefits team real plan-specific data rather than reliance solely on published trial populations, which often have higher adherence than real-world employees.

Key Metrics Every Plan Should Track From Day One

Tracking the right outcomes from the start is what separates plans that can demonstrate value from those that drop coverage after two years because the cost appeared unsustainable.

Collect and report quarterly: (1) number of members enrolled, (2) mean percentage weight loss at 16 weeks and 12 months, (3) 12-month persistence rate, (4) change in average A1c and systolic blood pressure for the enrolled cohort, (5) hospitalizations for cardiovascular events in the enrolled cohort versus a matched non-enrolled control group, and (6) net drug spend versus avoided downstream claims.

The Endocrine Society's 2023 guideline recommends that obesity treatment programs collect at minimum: body weight, waist circumference, blood pressure, fasting glucose, and lipid panel at baseline and at each follow-up visit [13]. These are the same data points an employer needs to build an actuarial case for continued or expanded coverage.